SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : BMY (bristol myers squibb) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (125)7/27/2017 11:45:59 AM
From: Miljenko Zuanic  Respond to of 194
 
Not to forget that marker analysis and prediction of the response magnitude (RR and OS) for combos (going for 2 drugs to 4-5 drugs combo) will be MUST. To justify significant rise in the treatment cost, one need clear proof and evidence that drugs combo works. Long way to go!

For BMY, the real Q is CTLA-4 true part of that combos? No Qs and doubts, Nivo is!



To: Miljenko Zuanic who wrote (125)8/29/2017 11:29:02 AM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 194
 
I want to thanks all those who shorted at 2Q-results, so give me a chance to add @52!


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News